Neurorestoration Drug Composition for Blood-Brain Barrier Limits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological approaches for treating central nervous system diseases are limited by the inability of drugs to cross the blood-brain barrier in sufficient quantities, and there is a need for effective combinatorial pharmacotherapy to enhance neurorestoration processes such as neurogenesis, synaptogenesis, and remyelination.
Innovation Solution
A combinatorial pharmacological composition combining Cilostazol, Metformin, Telmisartan, and Duloxetine to concurrently modulate multiple mechanisms of action, including improving blood flow, resolving inflammation, and promoting the creation of neurons, axons, and myelin sheaths, thereby enhancing neuroplasticity and neurorestoration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If single molecule pharmacological agents are used to treat CNS diseases, then the development process is simpler, but the therapeutic effectiveness is insufficient due to inability to cross blood-brain barrier adequately
Solution Approach 1:
The patent combines multiple pharmacological agents (Cilostazol, Metformin, Telmisartan, and Duloxetine) into a single combinatorial composition that achieves synergistic effects. This merging of multiple molecules overcomes the limitation of single molecules failing to adequately cross the blood-brain barrier or provide comprehensive therapeutic coverage for neurorestoration processes.
Solution Approach 2:
The combinatorial composition is designed to simultaneously address multiple neurorestoration mechanisms including neurogenesis, synaptogenesis, remyelination, and anti-inflammation. This multi-functional approach allows a single composition to tackle diverse aspects of CNS disease pathology that single molecules cannot achieve alone.
2Reliability
If combinatorial pharmacological compositions are used to enhance neurorestoration, then therapeutic effectiveness is improved, but the complexity of the pharmacological formulation increases
Solution Approach 1:
Four distinct pharmacological agents with different mechanisms of action are merged into a single composition formulation. Cilostazol provides PDE inhibition and anti-platelet effects, Metformin contributes AMPK activation and anti-diabetic properties, Telmisartan provides AT1 receptor blocking, and Duloxetine offers SNR inhibition. This merging achieves comprehensive neurorestoration while managing formulation complexity through unified delivery.
3Adaptability or versatility
If multiple drugs are combined to target different mechanisms of action, then comprehensive neurorestoration is achieved, but the risk of drug interactions and side effects increases
Solution Approach 1:
The patent acknowledges and manages potential drug interactions by selecting compounds with complementary mechanisms that synergistically enhance neurorestoration. The combination of PDE inhibition, AMPK activation, AT1 blocking, and SNR inhibition creates a coordinated effect that addresses multiple neurorestoration pathways simultaneously, converting potential interaction risks into enhanced therapeutic benefits.
Data Source
AI summary
One embodiment provides a neurorestoration compound or composition implementing multiple neuroplasticity inducing mechanisms of action including a mixture of pharmacologically effective amounts of Cilostazol and Metformin and Telmisartan. A second embodiment provides a neurorestoration compound or composition implementing multiple neuroplasticity inducing mechanisms of action including a mixture of pharmacologically effective amounts of Cilostazol and Metformin and Duloxetine. The neurorestoration compound implementing multiple neuroplasticity inducing mechanisms of action is believed to be particularly well suited for stroke rehabilitation.